Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in LeMaitre Vascular, Inc., Omnicell or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how LeMaitre Vascular, Inc., Omnicell and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About LeMaitre Vascular, Inc., Omnicell and Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Latest Health Care Equipment & Supplies and LeMaitre Vascular, Inc., Omnicell, Inc. Stock News

As of July 31, 2026, LeMaitre Vascular, Inc. had a $2.3 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. LeMaitre Vascular, Inc.’s stock is up 24.9% in 2026, up 6% in the previous five trading days and up 23.61% in the past year.

Currently, LeMaitre Vascular, Inc.’s price-earnings ratio is 37.2. LeMaitre Vascular, Inc.’s trailing 12-month revenue is $256.3 million with a 24.3% net profit margin. Year-over-year quarterly sales growth most recently was 11.2%. Analysts expect adjusted earnings to reach $3.000 per share for the current fiscal year. LeMaitre Vascular, Inc. currently has a 1.0% dividend yield.

As of July 31, 2026, Omnicell, Inc. had a $1.6 billion market cap, putting it in the 51st percentile of all stocks. Omnicell, Inc.’s stock is down 21.9% in 2026, down 13.7% in the previous five trading days and up 19.09% in the past year.

Currently, Omnicell, Inc.’s price-earnings ratio is 80.4. Omnicell, Inc.’s trailing 12-month revenue is $1.2 billion with a 3.1% net profit margin. Year-over-year quarterly sales growth most recently was 14.9%. Analysts expect adjusted earnings to reach $2.305 per share for the current fiscal year. Omnicell, Inc. does not currently pay a dividend.

How We Compare LeMaitre Vascular, Inc., Omnicell and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at LeMaitre Vascular, Inc., Omnicell and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

LeMaitre Vascular, Inc., Omnicell and Inc. Stock Value Grades

Company	Ticker	Value
LeMaitre Vascular, Inc.	LMAT	F
Omnicell, Inc.	OMCL	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

LeMaitre Vascular, Inc. has a Value Score of 12, which is Ultra Expensive. Omnicell, Inc. has a Value Score of 45, which is Average.

The Value Stock Winner: No Clear Winner

Neither LeMaitre Vascular, Inc., Omnicell or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if LeMaitre Vascular, Inc., Omnicell or Inc. is the better investment when it comes to value.

LeMaitre Vascular, Inc., Omnicell and Inc. Growth Grades

Company	Ticker	Growth
LeMaitre Vascular, Inc.	LMAT	A
Omnicell, Inc.	OMCL	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

LeMaitre Vascular, Inc. has a Growth Score of 89, which is Very Strong. Omnicell, Inc. has a Growth Score of 77, which is Strong.

The Growth Grade Winner: LeMaitre Vascular, Inc.

As you can clearly see from the Growth Grade breakdown above, LeMaitre Vascular, Inc. has a more attractive growth grade than Omnicell, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, LeMaitre Vascular, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

LeMaitre Vascular, Inc., Omnicell and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
LeMaitre Vascular, Inc.	LMAT	C
Omnicell, Inc.	OMCL	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

LeMaitre Vascular, Inc. has a Earnings Estimate Score of 51, which is Neutral. Omnicell, Inc. has a Earnings Estimate Score of 93, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: Omnicell, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Omnicell, Inc. has a better Earnings Estimate Revisions Grade than LeMaitre Vascular, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Omnicell, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other LeMaitre Vascular, Inc., Omnicell and Inc. Grades

In addition to Value, Growth and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether LeMaitre Vascular, Inc., Omnicell and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, LeMaitre Vascular, Inc., Omnicell or Inc. Stock?

Overall, LeMaitre Vascular, Inc. stock has a Value Score of 12, Growth Score of 89 and Estimate Revisions Score of 51.

Omnicell, Inc. stock has a Value Score of 45, Growth Score of 77 and Estimate Revisions Score of 93.

Comparing LeMaitre Vascular, Inc., Omnicell and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.